Table 1.
Obesity and its measurement indexes with the risk of different breast cancer subtypes.
| No. | Author | Patients(N) | Region | Menopausal status | Comparison | Molecular subtype | Measurement | 95%CI | P | Ref |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Agresti R. et al. | 1779 | Italy | Pre-menopausal | BMI≥25 vs. BMI<25 | LuminalB(HER2-) | OR=1.30 | 0.79-2.18 | N/A | (13) |
| LuminalB(HER2+) | OR=1.78 | 0.88-3.63 | N/A | |||||||
| HER2+(non-luminal) | OR=1.89 | 0.78-4.60 | N/A | |||||||
| TNBC | OR=3.04 | 1.43-6.43 | N/A | |||||||
| WC≥80cm vs. WC<80cm | LuminalB(HER2-) | OR=2.55 | 1.53-4.24 | N/A | ||||||
| LuminalB(HER2+) | OR=2.11 | 1.03-4.35 | N/A | |||||||
| HER2+(non-luminal) | OR=1.28 | 0.50-3.27 | N/A | |||||||
| TNBC | OR=1.03 | 0.42-2.53 | N/A | |||||||
| Post-menopausal | BMI≥25 vs. BMI<25 | LuminalB(HER2-) | OR=1.51 | 1.14-2.00 | N/A | |||||
| LuminalB(HER2+) | OR=1.20 | 0.76-1.92 | N/A | |||||||
| HER2+(non-luminal) | OR=1.43 | 0.79-2.57 | N/A | |||||||
| TNBC | OR=1.11 | 0.65-1.90 | N/A | |||||||
| WC≥80cm vs. WC<80cm | LuminalB(HER2-) | OR=1.17 | 0.75-1.81 | N/A | ||||||
| LuminalB(HER2+) | OR=0.82 | 0.41-1.63 | N/A | |||||||
| HER2+(non-luminal) | OR=1.36 | 0.50-3.69 | N/A | |||||||
| TNBC | OR=0.89 | 0.41-1.95 | N/A | |||||||
| 2 | Chen H. et al. | 4557 | USA | Both | Type 2 DM vs. non-DM | ER+/HER2+ | OR=0.77 | 0.40-1.48 | <0.05 | (17) |
| TNBC | OR=1.38 | 1.01-1.89 | <0.05 | |||||||
| H2E | OR=1.38 | 0.93-2.06 | <0.05 | |||||||
| 3 | Maskarinec G. et al. | 681 | USA | Both | Type 2 DM in subtypes | ER+/PR+ | HR=1.17 | 1.05-1.29 | N/A | (18) |
| ER-/PR- | HR=1.03 | 0.83-1.26 | N/A | |||||||
| ER+/PR- or ER-/PR+ | HR=1.01 | 0.81-1.28 | N/A | |||||||
| 4 | Michels K.B. et al. | 116488 | USA | Both | Type 2 DM vs. non-DM | ER+ | HR=1.22 | 1.01-1.47 | N/A | (19) |
| ER- | HR=1.13 | 0.79-1.62 | N/A | |||||||
| 5 | Millikan R.C. et al. | 3446 | USA | Pre-menopausal | WHR≥0.84 vs. WHR<0.84 | LuminalB | OR=0.90 | 0.40-1.80 | N/A | (20) |
| HER2+(non-luminal) | OR=0.90 | 0.40-2.20 | N/A | |||||||
| TNBC | OR=1.90 | 1.00-3.60 | N/A | |||||||
| Post-menopausal | WHR≥0.84 vs. WHR<0.84 | LuminalB | OR=0.50 | 0.20-0.90 | N/A | |||||
| HER2+(non-luminal) | OR=0.50 | 0.30-1.00 | N/A | |||||||
| TNBC | OR=1.40 | 0.70-2.70 | N/A | |||||||
| 6 | Munsell M.F. et al. | / | / | Pre-menopausal | BMI≥30 vs. BMI<25 | ER+/PR+ | RR=0.78 | 0.67-0.92 | 0.67 | (21) |
| ER-/PR- | RR=1.06 | 0.70-1.60 | 0.004 | |||||||
| Post-menopausal | BMI≥30 vs. BMI<25 | ER+/PR+ | RR=1.39 | 1.14-1.70 | 0.001 | |||||
| ER-/PR- | RR=0.98 | 0.78-1.22 | 0.02 | |||||||
| 7 | Palmer J.R. et al. | 1851 | USA | Both | Type 2 DM vs. non-DM | ER+ | HR=1.02 | 0.80-1.31 | N/A | (22) |
| ER- | HR=1.43 | 1.03-2.00 | N/A | |||||||
| 8 | Pierobon M. et al. | 3845 | USA | Pre-menopausal | BMI≥30 vs. BMI<30 | TNBC | OR=1.43 | 1.23-1.65 | N/A | (23) |
| 9 | Rosner B. et al. | 77232 | USA | Pre-menopausal | Per 25 lbs weight gain | ER+/PR+ | RR=1.13 | 0.89-1.43 | 0.32 | (24) |
| ER+/PR- | RR=2.19 | 1.33-3.61 | 0.002 | |||||||
| ER-/PR- | RR=1.61 | 1.09-2.38 | 0.016 | |||||||
| 10 | Suzuki R. et al. | 41594 | Japan | Post-menopausal | Per increment of 5kg/m2 | ER+/PR+ | RR=2.24 | 1.50-3.34 | N/A | (25) |
| ER+/PR- | RR=0.63 | 0.31-1.27 | N/A | |||||||
| ER-/PR- | RR=0.67 | 0.38-1.17 | N/A |
BMI, Body mass index; ER, Estrogen receptor; HER2, Human epidermal growth factor 2; N/A, Not applicable; OR, Odds ratio; PR, Progesterone receptor; RR, Relative risk; TNBC, Triple negative breast cancer; WC, Waist circumference.